License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2012

License, Collaboration and Other Revenue

In accordance with these agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended September 30,				Nine months ended September 30,
Partner	Drug or Drug Candidate	2012		2011		2012		2011
Baxter Healthcare	Hemophilia	$	741	$	3,556	$	5,794	$	4,486
Roche	PEGASYS® and MIRCERA®		2,011		1,283		5,134		3,849
Amgen, Inc.	Neulasta®		1,250		1,250		3,750		3,750
Affymax, Inc.	Omontys®		198		2,440		2,610		3,343
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		714		750		2,257		2,250
Other			1,218		7,567		4,645		11,997
License, collaboration, and other revenue		$	6,132	$	16,846	$	24,190	$	29,675